Page 1

PRESS RELEASE BIOMÉRIEUX bioMérieux - 2020 Financial Results € 3,118 million in full - year 2020 sales , up 19.7 % like - for - like Robust sales performance in the fourth quarter , with organic growth of 20.5 % led by sales of molecular biology reagents Contributive operating income before non - recurring items up nearly 58 % to € 613 million , or 19.6 % of sales for the year Strong cash flow resulting in a financial debt free position at year - end " " 2021 guidance : In a persistently uncertain business environment , sales are expected to increase by between 5 % and 8 % at constant exchange rates and scope of consolidation in 2021. Growth in the first half of 2021 should remain steady , on a par with the trend of Q4 2020 . 2021 Contributive operating income before non - recurring items should be in line with 2020 , at current exchange rates . Alexandre Mérieux , Chairman and Chief Executive Officer , said : “ In the unprecedented crisis the world has been facing for a year , bioMérieux has been strongly mobilized and has proven once again how relevant its solutions are . Our positioning as an In Vitro Diagnostics specialist and our development of solutions adapted to the detection of COVID - 19 has allowed us to deliver a remarkable commercial and financial performance . In an uncertain context with regards to the evolution of the pandemic , bioMérieux and its teams are confidently committed to responding to the public health challenges posed by infectious diseases , by placing diagnostics at the heart of the patient care strategy . " Marcy l'Etoile ( France ) , February 24 , 2021 - The Board of Directors of bioMérieux , a world leader in the field of in vitro diagnostics , met on February 23 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial statements for the year ended December 31 , 2020 . Consolidated data 2020 2019 In € millions % Change As reported Net Sales 3,118 2,675 + 16,6 % Contributing operating income before non- 613 recurring items ( 2 ) % 19.6 % 389 14.5 % + 57.6 % sales Operating incomel ( 3 ) Net income , group share Diluted net income per share ( in € ) 523 371 +49.1 % 404 273 + 48.2 % 3.41 € 2.30 € ( 1 ) Contributive operating income before non - recurring items corresponds to operating income before non - recurring items relating to the BioFire acquisition . ( 2 ) Operating income is the sum of contributive operating income before non - recurring items , BioFire purchase price amortization expense and " material , extraordinary and non - recurring items " recognized in " Other non - recurring income and expenses from operations , net " .